aTyr Pharma (ATYR)
(Delayed Data from NSDQ)
$3.04 USD
-0.08 (-2.56%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $3.02 -0.02 (-0.66%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
ATYR 3.04 -0.08(-2.56%)
Will ATYR be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ATYR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATYR
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates
Is aTyr Pharma (ATYR) Outperforming Other Medical Stocks This Year?
ATYR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ATYR
Promising Outlook for aTyr Pharma’s Efzofitimod in Pulmonary Sarcoidosis: Buy Rating Affirmed
aTyr Pharma management to meet virtually with Piper Sandler
aTyr Pharma management to meet virtually with Piper Sandler
Wall Street Analysts Are Bullish on Top Healthcare Picks
Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and aTyr Pharma (ATYR)